Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 28,812 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed No phase listed Observational Results available

Real World Glycemic Effectiveness of Linagliptin

NCT03338803
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 26, 2026, 4:54 PM EDT
Terminated Phase 1 Interventional

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

NCT02782403
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
Interventions
Axitinib, Bosutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 1 Interventional

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

NCT03088527
View directory record Official record
Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
RAD140
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 26, 2026, 4:54 PM EDT
Recruiting Not applicable Interventional

Effects of Acupuncture on Symptoms of Stable Angina

NCT06311461
View directory record Official record
Conditions
Angina, Stable
Interventions
Acupuncture, Attention control
Procedure · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 26, 2026, 4:54 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islets of Langerhans transplantation
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 26, 2026, 4:54 PM EDT
Terminated Phase 4 Interventional Results available

Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators

NCT01557842
View directory record Official record
Conditions
Ventricular Tachycardia, Ischemic
Interventions
Drug Treatment, Catheter Ablation
Drug · Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Early Phase 1 Interventional Results available

Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

NCT03440970
View directory record Official record
Conditions
Decompensated Heart Failure
Interventions
Lysine Chloride, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 3 Interventional

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

NCT00004583
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
42
States / cities
Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 26, 2026, 4:54 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Single Lumen Midline Catheter vs Long Peripheral Intravenous Cather for Difficult Intravenous Access in the ED

NCT06668766
View directory record Official record
Conditions
Difficult Intravenous Access, Midline Catheter, Peripheral Intravenous Catheter, Emergency Department Patient
Interventions
10-cm Single Lumen Mildine, 4.78 cm Long Peripheral Intravenous Catheter
Device
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

NCT01749566
View directory record Official record
Conditions
HIV
Interventions
maraviroc
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 26, 2026, 4:54 PM EDT
Terminated Phase 2 Interventional Results available

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756
View directory record Official record
Conditions
Schizophrenia
Interventions
LY500307 150mg, LY500307 75mg, Placebo, LY500307 25mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Results available

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

NCT00420056
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
PD-0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Not applicable Interventional Results available

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

NCT01471522
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions
cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
5,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 26, 2026, 4:54 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00002451
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Miami, Florida • Albany, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Battlefield Acupuncture for Low Back Pain

NCT03491124
View directory record Official record
Conditions
Low Back Pain, Chronic Low Back Pain
Interventions
Auricular Acupuncture, Sham Treatment
Other
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Andrews Air Force Base, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

NCT03679780
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 26, 2026, 4:54 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT00528879
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 26, 2026, 4:54 PM EDT